Background: While our previous research has demonstrated that the NLRP3 inflammasome
is involved in epilepsy progression, the effects of the specific NLRP3 inhibitor CY-09 remain
poorly understood. Therefore, the aim of the present study was to investigate the efficacy of
CY-09 against pentylenetetrazole (PTZ)-induced neuronal loss in mice.
Methods: The expressions of the proinflammatory factors interleukin-1β and interleukin-18 were
examined by western blot and enzyme-linked immunosorbent assays. Western blot analysis was applied
to detect the level of astrocyte activation. Neuronal apoptosis was determined by western blot
analysis combined with immunostaining specific for neuronal nuclei.
Results: We found that CY-09 ameliorated the progression of the kindling process and inhibited
PTZ-induced neuronal loss by attenuating the activation of astrocytes and the secretion of NLRP3-
Conclusion: These findings indicate that CY-09 may represent an important treatment agent for
epilepsy and other NLRP3 inflammasome-associated diseases.